1 active not recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Nasopharyngeal Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Nasopharyngeal Squamous Cell Carcinoma trials Research Report on Recurrent Nasopharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-11-03 |
Carcinoma (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Lymphoid Interstitial Pneumonia (1) · Mouth Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Oropharyngeal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Mouth Diseases (1) · Nasopharyngeal Diseases (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Otorhinolaryngologic Diseases (1) · Otorhinolaryngologic Neoplasms (1) · Pharyngeal Diseases (1) · Pharyngeal Neoplasms (1) · Respiratory Tract Diseases (1)
(225)Ac-DOTA-c(RGDyK) (1) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bevacizumab (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Disulfides (1) · Docetaxel (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Platinum (1) · Specimen Handling (1) · atezolizumab (1)
National Cancer Institute (NCI) (1)
United States (1)
Aarti Bhatia (1)
U10CA180820 (1)